CTC BIO, INC. Logo

CTC BIO, INC.

Develops and manufactures human and animal health products using microbial fermentation.

060590 | KO

Overview

Corporate Details

ISIN(s):
KR7060590007
LEI:
Country:
South Korea
Address:
경기도 화성시 동탄첨단산업1로 27 금강펜테리움IX타워 A동 901호, 화성시

Description

CTC BIO, INC. is a company specializing in the development, manufacturing, and distribution of products for human and animal health. The company leverages core technologies in microbial fermentation and coating to create its product portfolio. Key business areas include human pharmaceuticals, functional foods, and a comprehensive range of animal health solutions. The animal health division offers veterinary medicines, such as antibiotics and coccidiostats, feed additives, and innovative bacteriophage-based products for disease control. In the human health sector, the company provides various pharmaceuticals and is recognized for its advanced manufacturing of probiotics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2025-09-03 00:00
주식등의대량보유상황보고서(일반)
Korean 82.3 KB
2025-09-01 00:00
주식등의대량보유상황보고서(일반)
Korean 89.9 KB
2025-08-12 00:00
[기재정정]사업보고서 (2024.12)
Korean 2.1 MB
2025-08-12 00:00
반기보고서 (2025.06)
Korean 1.7 MB
2025-07-25 00:00
단기차입금증가결정
Korean 8.9 KB
2025-05-14 00:00
분기보고서 (2025.03)
Korean 1.7 MB
2025-04-16 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.7 KB
2025-04-16 00:00
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.4 KB
2025-04-16 00:00
주식등의대량보유상황보고서(일반)
Korean 103.9 KB
2025-04-16 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-04-16 00:00
주식등의대량보유상황보고서(일반)
Korean 92.9 KB
2025-03-31 00:00
정기주주총회결과
Korean 18.6 KB
2025-03-21 00:00
감사보고서제출
Korean 25.0 KB
2025-03-21 00:00
사업보고서 (2024.12)
Korean 587.2 KB

Automate Your Workflow. Get a real-time feed of all CTC BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CTC BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CTC BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.